Stephanie Gladden, APRN
Family · Martinsburg, WVNPI 1730119447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$1K
- AstraZeneca$943
- Novo Nordisk$444
- Exact Sciences$353
- Bayer$336
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,285100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 83 | $1,269 |
| AbbVie(2 entities) | 63 | $1,033 |
| AstraZeneca | 53 | $943 |
| Novo Nordisk | 29 | $444 |
| Exact Sciences | 13 | $353 |
| Bayer | 15 | $336 |
| GSK | 20 | $330 |
| Amgen | 17 | $324 |
| Astellas Pharma US Inc | 13 | $271 |
| Pfizer | 16 | $253 |
| Otsuka America Pharmaceutical, Inc. | 12 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $169 |
| Boehringer Ingelheim | 9 | $159 |
| Abbott | 8 | $151 |
| Novartis | 9 | $141 |
| Esperion Therapeutics, Inc. | 5 | $99 |
| Johnson & Johnson | 5 | $78 |
| Kowa Pharmaceuticals America, Inc. | 5 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| Medtronic | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Agios Pharmaceuticals, Inc. | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Verona Pharma, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $32 |
| Cranial Technologies, Inc | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Genentech USA, Inc. | 2 | $18 |
| Merck | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Organon | 1 | $11 |
How this compares
$7,289 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 43 | $55,713 |
| EliquisApixaban | 20 | $33,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $28,203 |
| OzempicSemaglutide | 24 | $27,111 |
| FarxigaDapagliflozin Propanediol | 27 | $23,589 |
| XareltoRivaroxaban | 12 | $18,861 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $17,246 |
| JardianceEmpagliflozin | 11 | $9,910 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,207 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $7,838 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,018 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,421 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $6,086 |
| MovantikNaloxegol Oxalate | 12 | $4,692 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $3,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,269 | $55,71343 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $943 | $37,88258 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $330 | $34,62450 claims |
| PfizerEliquis | $253 | $33,21320 claims |
| Novo NordiskOzempic | $444 | $27,11124 claims |
| Johnson & JohnsonXarelto | $78 | $18,86112 claims |
| Boehringer IngelheimJardiance | $159 | $9,91011 claims |
| AbbVieSynthroid | $1,033 | $1,71113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Martinsburg
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.